Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
Genocea Biosciences, Inc. GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escal...